Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Withdrawal of ivarmacitinib vs csDMARDs in RA patients with low disease activity
ChiCTR2600119971Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ivarmacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Proportion of subjects maintaining low disease activity (DAS28-CRP ≤ 3.2) at Week 48. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2600119971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119971.